Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548657 | 1.00 | OPRM1 (0.47) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL3548653 | 1.00 | OPRM1 (0.47) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL1995216 | 0.88 | OPRM1 (0.47) | OPRM1CHRM2CHRM3ACHESIGMAR1 | |
| SCHEMBL3524495 | 0.84 | ACHE (0.53) | OPRM1CHRM2CHRM3ACHEBCHE | |
| SCHEMBL4397749 | 0.84 | ACHE (0.53) | OPRM1CHRM2CHRM3ACHEBCHE | |
| SCHEMBL7226848 | 0.77 | ALDH1A1 (0.55) | ACHEBCHEALDH1A1KDM4E | |
| SCHEMBL3547834 | 0.77 | ALDH1A1 (0.55) | ACHESIGMAR1BCHEALDH1A1 | |
| SCHEMBL3547840 | 0.77 | ALDH1A1 (0.55) | ACHESIGMAR1BCHEALDH1A1 | |
| SCHEMBL3547837 | 0.77 | ALDH1A1 (0.55) | ACHESIGMAR1BCHEALDH1A1 | |
| SCHEMBL8844605 | 0.77 | OPRM1 (0.50) | OPRM1CHRM2CHRM3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732461-B2 | (4S)-4-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-3-fluoro-4-hydroxy-4,5-dihydro-7H-pyrrolo[3,2,1-de]-1,5-naphthyridin-7-one, used in the treatment of bacterial infections caused by a wide range of organisms including both gramnegative and grampositive bacteria | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137568-A1 | Tryclic Nitrogen Containing Compounds and their Use as Antibacterials | NRDC, NACA, ASNS | OPRM1 92/4885CHRM2 4199/4885CHRM3 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.